Will biosimilars improve public health? Policy makers should look to that question as they sort through possible solutions, the authors say.
There are several possible solutions to encouraging the use of biosimilars in the United States, according to a newly published article in the latest issue of the AMA Journal of Ethics.
While the authors hold out hope that some combination of new policies and regulatory changes will spur increased access and lower prices, interestingly, they also propose that if all else fails, perhaps it would then be time to regulate the prices of originator biologics after a certain period of exclusivity.
A similar argument has been made this year in a series of posts in Health Affairs, where some have called for regulating biosimilars in order to lower prices and increase access.
However, the political will to implement price regulation is scarce, notes the latest discussion on the topic, and so “encouraging increased competition in the biologics market with biosimilars remains the most promising mechanism to increase access to much-needed drugs,” the authors write.
Some of their recommendations, short of price regulation, include:
Acknowledging that some patients and physicians still have concerns about biosimilars, questioning safety and effectiveness, the authors say that postmarketing studies of biosimilars will continue to be necessary to evaluate these concerns. They note, however, that, so far, studies have found no meaningful safety and efficacy differences between a biosimilar and its respective originator biologic.
Will biosimilars improve public health? Policy makers should look to that question as they sort through possible solutions, the authors say. The high cost of biologics imposes a barrier to patient access and adherence; lower prices resulting from competition will reduce overall healthcare costs and could improve medication adherence, resulting in better health outcomes.
Reference
Zhai MZ, Sarpatwari A, Kesselheim AS. Why are biosimilars not living up to their promise in the US? AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.